The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.
 
Lucia Carril-Ajuria
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Deka Biosciences; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Neoleukin Therapeutics; Oncorena; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; Lilly; Merck Sharp & Dohme; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Aveo; Bristol-Myers Squibb/Medarex; Calithera Biosciences; Calithera Biosciences; Genentech; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; Pfizer; Pfizer; Regeneron; Seagen
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Frede Donskov
Research Funding - MSD Oncology (Inst)
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Ruiyun Jiang
Employment - Bristol-Myers Squibb
 
Chung-Wei Lee
No Relationships to Disclose
 
Heshani Desilva
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bellerophon Theraeutics (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - BMS; MSD